Retatrutide: what phase 2 trials measured
Retatrutide has been studied in phase 2 clinical trials involving adults with obesity and adults with type 2 diabetes. The obesity trial reported changes in body weight over 48 weeks; a separate diabetes trial assessed glycaemic control and weight over 36 weeks. These are measured outcomes in defined study populations, not a guarantee of an individual result, proof of long-term benefit, or evidence of approval. Retatrutide remains investigational. Research catalogue materials are not medicines and are not intended for human use.
Published: · Last reviewed:
Warning: These materials are strictly for in-vitro laboratory research. Not for human or veterinary use.
Retatrutide laboratory reference →
Weight change in an obesity phase 2 trial
In the 48-week phase 2 trial in adults with obesity, the primary endpoint was percentage change in body weight. The publication reported a mean change of −24.2% at week 48 in the 12 mg group and −2.1% with placebo. Those figures describe group averages in that particular trial, not an expected result for an individual. The study was a phase 2 investigation and does not by itself establish long-term outcomes or comparative superiority.
Glycaemic and weight endpoints in type 2 diabetes
A separate phase 2 study enrolled adults with type 2 diabetes and evaluated HbA1c change at week 24 as its primary endpoint, with body-weight change also assessed. The trial reported reductions in HbA1c and body weight across retatrutide groups, but population, study design, follow-up and endpoints differ from the obesity trial. Results from these two studies should not be combined as if they came from one population or one treatment comparison.
What these findings cannot establish
Phase 2 results are early clinical evidence. The trials were limited in size and duration, and their findings cannot establish long-term safety, lasting outcomes, effectiveness in populations not studied, or superiority to Ozempic or another medicine. Gastrointestinal adverse events were among those reported in the obesity study. Retatrutide has no approved medicine label in the cited regulatory source set. This page is an educational summary, not treatment or use guidance.
Research references
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. — The New England Journal of Medicine / PubMed, PMID 37366315
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. — The Lancet / PubMed, PMID 37385280
Reference questions
Do the phase 2 weight figures predict what an individual will experience?
No. They are group-level trial results in a selected study population over a defined period. They do not predict an individual outcome or establish a guaranteed effect.
Do these trials show that retatrutide is better than Ozempic?
No. The cited phase 2 studies were not direct head-to-head trials against Ozempic, so they do not establish comparative superiority.
Is retatrutide an approved medicine?
Retatrutide remains investigational in the cited publications. Trial findings do not constitute regulatory approval, and catalog research materials are not medicines or for human use.